Blood Pressure and Pulse Donor Eligibility Requirements: Compliance Policy; Draft Guidance for Industry; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA or Agency) is correcting a notice that appeared in the Federal Register of Tuesday, May 24, 2022. The document announced the availability of a draft guidance entitled "Blood Pressure and Pulse Donor Eligibility Requirements: Compliance Policy; Draft Guidance for Industry." The draft guidance document was published with incorrect information of a comment period due date. This document corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 113 (Monday, June 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 113 (Monday, June 13, 2022)]
[Notices]
[Page 35787]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12619]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-D-0362]
Blood Pressure and Pulse Donor Eligibility Requirements:
Compliance Policy; Draft Guidance for Industry; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is correcting
a notice that appeared in the Federal Register of Tuesday, May 24,
2022. The document announced the availability of a draft guidance
entitled ``Blood Pressure and Pulse Donor Eligibility Requirements:
Compliance Policy; Draft Guidance for Industry.'' The draft guidance
document was published with incorrect information of a comment period
due date. This document corrects that error.
FOR FURTHER INFORMATION CONTACT: Myrna Hanna, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-
402-7911.
SUPPLEMENTARY INFORMATION: In the Federal Register of May 24, 2022 (87
FR 31567), in FR Doc. 2022-11118, on page 31567, the following
correction is made:
1. On page 3156, in the first column, the DATES caption is
corrected to read:
DATES: Submit either electronic or written comments on the draft
guidance by July 25, 2022, to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.
Dated: June 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-12619 Filed 6-10-22; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.